MedWatch

Bavarian Nordic and other vaccine companies suffer as Covid-19 restrictions ease: "You might ask whether the ship has sailed"

Investors are punishing Bavarian Nordic on the stock exchange, and one vaccine professor asks whether now is too late for the firm to get into the lucrative Covid-19 vaccine market.

Bavarian Nordic is headquartered north of Copenhagen. The Danish biotech company still hopes to succeed with its Covid-19 vaccine | Photo: Philip Davali/Ekstra Bladet, Philip Davali

While Danes celebrate the prospect of a life without pandemic restrictions, the hope of a glowing future for Bavarian Nordic’s Covid-19 vaccine is slowly being extinguished.

”You might ask whether the ship has sailed for Bavarian Nordic. The technologies that have the strongest position are those that can quickly be adapted to a new variant,” says Camilla Foged, a professor of vaccine design and delivery at the University of Copenhagen.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

In a world of options, Genmab's CEO chose partnerships

In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.

Analyst predicts slow start for Leo Pharma's Adtralza in UK

The take-up of Leo Pharma’s atopic eczema drug Adtralza in the UK will be slow-going, according to analyst bureau Global Data, after the British institute NICE released draft guidance where it was not recommend it as a standard treatment in England and Wales.

Further reading

Related articles

Latest news

See all jobs